News

Long-term treatment with Vykat XR (diazoxide choline) safely provides lasting relief from the uncontrollable hunger and behavioral struggles associated with Prader-Willi syndrome (PWS), according to new clinical data. Recent trial results also show that patients who temporarily paused the treatment quickly regained its benefits after restarting. That’s according…

The first participant has been dosed in a proof-of-concept, open-label Phase 2a clinical trial testing Consynance Therapeutics’ experimental oral therapy CSTI-500 in adolescents and adults with Prader-Willi syndrome (PWS). Supported in part by a venture philanthropy investment from the Foundation for Prader-Willi Research (FPWR), the Phase 2a study…

Treatment with setmelanotide helped reduce uncontrollable hunger, known as hyperphagia, and also eased anxiety in children and adults with obesity due to Prader-Willi syndrome (PWS). The Rhythm Pharmaceuticals‘ experimental injection therapy was also shown to reduce body fat and preserve lean mass in individuals with PWS. That’s according…

Most infants with Prader-Willi syndrome (PWS) experience sleep-disordered breathing and obstructive sleep apnea before ever starting growth hormone therapy, a small Belgian study shows. The findings challenge previous suggestions that growth hormone therapy, a standard treatment for PWS, is what primarily drives the risk of obstructive sleep apnea (OSA),…

Adults and children with Prader–Willi syndrome (PWS) had a favorable metabolic profile — a measure of how well the body processes energy — compared with controls in a small study from Bulgaria. Still, people with PWS who had more abdominal fat, reflected by a higher waist circumference, had markers…

Issues processing sensory input are a major contributing factor to irritability in people with Prader-Willi syndrome (PWS), according to a new study from Japan. The research indicates that these sensory challenges are stronger predictors of PWS-related irritability than the specific genetic abnormality underlying the disease. Publishing their findings in…

The U.S. Food and Drug Administration has placed a full clinical hold on late-stage clinical trials of Aardvark Therapeutics’ oral therapy candidate ARD-101 in patients with Prader-Willi syndrome (PWS) and hyperphagia, or insatiable hunger. The company had voluntarily paused…

Tonix Pharmaceuticals has pushed back the planned start of a Phase 2 clinical trial testing its oxytocin-containing TNX-2900 nasal spray in children and adolescents with Prader-Willi syndrome (PWS). Tonix had expected the U.S.-based study, which has been cleared by the U.S. Food and Drug Administration (FDA), to start…

Infants younger than 6 months with Prader-Willi syndrome (PWS) showed increased blood flow in brain regions involved in movement, motivation and reward, emotional processing, and social behaviors, a study in France reports. Data also showed that blood flow in one brain region was associated with oral-motor performance, including sucking…

May is Prader-Willi Syndrome (PWS) awareness month, offering families and advocates an opportunity to raise visibility, share experiences, and drive change for those affected by the disease. Through the United in Action initiative, launched by the PWS Association USA (PWSA USA), supporters are encouraged to turn everyday connections…